At what enterprise value was GLEAMER acquired in 2026?

During the acquisition of GLEAMER by RADNET in 2026, the company was valued at an estimated revenue multiple of 5x - 12x. The transaction's Enterprise Value is estimated to be in the range of 100M - 350M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of GLEAMER when it was acquired by RADNET?

The exact EV/EBITDA multiple for GLEAMER is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was GLEAMER acquired by RADNET?

GLEAMER was acquired by RADNET in 2026.

What was the revenue of GLEAMER at the time of the deal?

The revenue of GLEAMER at the time of the deal is estimated to be in the range of 25M - 50M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the GLEAMER acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the GLEAMER deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.maddyness.com/2026/03/02/la-medtech-gleamer-passe-sous-pavillon-americain-pour-230-millions-deuros/

← DATABASE

Home Database Healthcare & PharmaGLEAMER

03/2026

GLEAMER acquired by RADNET

FRANCE Healthcare Services / Health Tech EV 100M - 350M EUR

Context

RadNet acquired Gleamer in an all-cash transaction to integrate its automated diagnostic and reporting solutions into the DeepHealth platform. The acquisition aims to create the world's largest provider of clinical radiology AI solutions by combining RadNet's massive US imaging volume with Gleamer's advanced multi-modality software. Gleamer will now operate as RadNet’s French subsidiary, with founder Christian Allouche continuing to lead development from Paris. The strategic goal is to automate routine imaging workflows—specifically plain-film X-rays, which represent 25% of RadNet’s volume—to drive significant cost efficiencies and diagnostic accuracy.

Supernova Invest / Heal Capital had previously taken control of the company through an LBO in 2023.

GLEAMER, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Gleamer is a leading French MedTech company specializing in artificial intelligence for medical imaging. Its "Copilot" platform provides automated diagnostic assistance for radiologists across multiple modalities, including X-ray, Mammography, and MRI. Prior to this acquisition, Gleamer consolidated the market by acquiring Pixyl and Caerus Medical in 2025, expanding its expertise into neuro and lumbar MRI. The company serves over 700 clients in 44 countries, with its solutions supporting over 25 clinical indications.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2025

2024

Other operations with GLEAMER

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
06/2023	SUPERNOVA INVEST / HEAL CAPITAL	GLEAMER	FRANCE	Healthcare Services	Gleamer raised €27 million in Series B funding to broaden its AI solution portfolio and accelerate global commercial development. The strategic plan involves expanding the software suite to include CT scans and mammography, aiming to cover 70% of radiologists' daily diagnostic needs. A significant portion of the capital is earmarked for strengthening commercial and technical teams in Europe and the United States, as well as deepening strategic partnerships with global medical imaging equipment manufacturers (OEMs).

REFERENCES

Valuation range: EV 100M - 350M EUR

Revenue range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of GLEAMER by RADNET are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: gleamer